AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00351910
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2008-12-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00351169
- Locations
- 🇪🇸
Research Site, Zamora, Spain
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
Phase 4
Completed
- Conditions
- HypertensionLeft Ventricular Hypertrophy
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT00348686
- Locations
- 🇰🇷
Research Site, Ulsan, Korea, Republic of
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Completed
- Conditions
- Hypercholesteremia
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3840
- Registration Number
- NCT00347217
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2010-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT00344773
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Symptom Adapted Therapy in GERD Patients
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 441
- Registration Number
- NCT00343161
- Locations
- 🇩🇪
Reseach Site, Urspringen, Germany
🇩🇪Research Site, Zwickau, Germany
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239
- Registration Number
- NCT00338130
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
AZD1152 in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Tumors
- Interventions
- Drug: AZD1152 part ADrug: AZD1152 part B
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 43
- Registration Number
- NCT00338182
- Locations
- 🇺🇸
Research Site, New York, New York, United States
Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome
Phase 4
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 370
- Registration Number
- NCT00335699
- Locations
- 🇰🇷
Research Site, Ulsan, Korea, Republic of
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Phase 2
Completed
- Conditions
- Endometrial Carcinoma
- First Posted Date
- 2006-06-07
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00334295
- Locations
- 🇩🇪
Research Site, Rostock, Germany
© Copyright 2025. All Rights Reserved by MedPath